cd4  (R&D Systems)

Journal: bioRxiv

Article Title: Systemic Translocation of S. aureus Drives Anti-CD4 Autoimmunity in Treated HIV Infection

doi: 10.1101/2025.08.04.668434

Figure Lengend Snippet: (A) Z-scored plasma levels of 87 autoantibodies in controls (n = 32), untreated PWH (n = 32), and ART-suppressed PWH (n = 53). (B) Anti-CD4 and anti-prothrombin IgG levels. (C) Anti-CD8 IgG levels. (D) Correlation between anti-CD4 IgG levels and CD4+ T cell counts. ANOVA and Spearman correlation tests were applied.

Article Snippet: The 96-well plate was coated with 1 μg/100 μL/well of recombinant mouse CD4 protein (Sino Biological, Wayne, PA) at 4°C overnight.

Techniques: Clinical Proteomics

Journal: bioRxiv

Article Title: Systemic Translocation of S. aureus Drives Anti-CD4 Autoimmunity in Treated HIV Infection

doi: 10.1101/2025.08.04.668434

Figure Lengend Snippet: Association of S. aureus serological and cellular markers with anti-CD4 IgG in PWH on ART. (A) Positive correlation between plasma anti-CD4 IgG and anti- S. aureus IgG levels. (B) Subgroup of HIV+/ART+ individuals shows elevated anti- S. aureus IgG. (C–D) B cell gene expression analysis reveals enriched immune pathways in PWH vs. controls. Spearman correlation and ANOVA were applied; P < 0.05.

Article Snippet: The 96-well plate was coated with 1 μg/100 μL/well of recombinant mouse CD4 protein (Sino Biological, Wayne, PA) at 4°C overnight.

Techniques: Clinical Proteomics, Gene Expression

Journal: bioRxiv

Article Title: Systemic Translocation of S. aureus Drives Anti-CD4 Autoimmunity in Treated HIV Infection

doi: 10.1101/2025.08.04.668434

Figure Lengend Snippet: C57BL/6J mice received i.p. injections of PBS, S. aureus PGN, or B. subtilis PGN twice weekly for 12 weeks (n = 8/group). (A–C) Serum levels of anti-CD4 IgG, total IgG, and anti-CD4 IgG subclasses. (D–E) Gating strategy and CD4+ T cell percentages in mesenteric lymph nodes, spleen, and blood. Student’s t-test and ANOVA were applied. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Article Snippet: The 96-well plate was coated with 1 μg/100 μL/well of recombinant mouse CD4 protein (Sino Biological, Wayne, PA) at 4°C overnight.

Techniques:

Journal: bioRxiv

Article Title: Systemic Translocation of S. aureus Drives Anti-CD4 Autoimmunity in Treated HIV Infection

doi: 10.1101/2025.08.04.668434

Figure Lengend Snippet: (A) Annexin V binding on IgG+CD4+ vs. IgG–CD4+ T cells. (B–D) Frequencies of IgG+CD4+ T cells in mesenteric lymph nodes, spleen, and blood. (E–G) Annexin V binding on IgG+CD4+ and IgG−CD4+ T cells in the same tissues. Student’s t-test and one-way ANOVA were applied.

Article Snippet: The 96-well plate was coated with 1 μg/100 μL/well of recombinant mouse CD4 protein (Sino Biological, Wayne, PA) at 4°C overnight.

Techniques: Binding Assay

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Inhibition assay of sCD4 and CD4-derived protein molecules against pseudotyped and infectious Ebola viruses (A) sCD4 (2D), soluble first two-domain CD4; sCD4 (4D), soluble four-domain CD4; CD4-Ig, first two-domain CD4 linked with human Fc region (Ig domain) ; CD4-IgG2, first two-domain CD4 with human Fc region (Ig domain); EBOV, Zaire Ebola virus; BDBV, Bundibugyo ebolavirus. All experiments were conducted in triplicates and the error bars represent standard deviations from three experiments. (B) sCD4 (4D) inhibits infectious Ebola virus infection. This experiment was conducted in BSL-4 containment in triplicates, and the error bars represent standard deviations.

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Inhibition, Derivative Assay, Virus, Infection

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Inhibition assay of CD4-mimetic small molecules against pseudotyped Ebola viruses (A) NBD-556 and analogs inhibiting EBOV infection. (B) Newly designed and synthesized compounds with phenyl ring substituted molecules in the region-I inhibiting EBOV. All experiments were conducted in triplicates and the error bars represent standard deviations from three experiments.

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Inhibition, Infection, Synthesized

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Specificity assay of CD4-IgG-2 and JRC-II-191 against pseudo-typed HIV, EBOV, VSV, and A-MLV CD4-mimetic molecules CD4-IgG2 and JRC-II-191 were evaluated against four different viruses: HIV (YU2), EBOV, VSV (vesicular stomatitis virus), and A-MLV (amphitropic murine leukemia virus). All experiments were conducted in triplicates and the error bars represent standard deviations from three experiments.

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Virus

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Binding affinity and kinetics assay of sCD4 (2D) and NBD-556 binding to EBOV receptor binding domain by biolayer interferometry Two-domain CD4 (sCD4-2D) (A) and NBD-556 (B) at two pH conditions, pH7.4 and pH6.1. Open circle in (B) was not included in the fit of the data. (See the BLI section for details).

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Binding Assay

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Binding competition assay of sCD4 and CD4-mimetic compounds with receptor NPC1 (A) sCD4, NBD-556, JRC-II-191, and DY-III-228 competing with NPC1 receptor. (B) Dose response (0, 10, 20, and 40 μM) of NBD-556 in binding competition with NPC1 receptor. (C) Comparison of wild-type (EGPDCM-WT) and mutant (EGPDCM-mut) (WF/AA, 86W/A, and 88F/A) receptor binding domain (RBD) of EBOV binding to the NPC1 receptor. The mutant (WF/AA) surface expression level was confirmed to be comparable to the wild type (see ). Representative of 3 experiments.

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Binding Assay, Competitive Binding Assay, Comparison, Mutagenesis, Expressing

Journal: iScience

Article Title: Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site

doi: 10.1016/j.isci.2025.112573

Figure Lengend Snippet: Molecular docking analysis of sCD4 and CD4mcs (A) Molecular docking analysis of sCD4 and CD4mcs binding to the EBOV-GP. sCD4 docking using HDOCK program. The docking energy is −150.41 kcal/mol. CD4mcs docking using AutoDock program. (a) sCD4-RBD ribbon model; (b) sCD4-RBD surface binding model; (c) sCD4-RBD interactions: hydrogen bond: GP T83:OG1-CD4 L44:N (green) and salt bridge: GP K84:NZ-CD4 D56:OD2 (brown) ; (d) NBD-556 docking ribbon model (−6.477 kcal/mol); (e) NBD-556 docking surface model; and (f), superimposed of NBD-556 (yellow), JRC-II-191 (magenta), and DY-III-228 (cyan). (B) Comparisons of two receptor binding sites of CD4bs and NPC1-bs. (a) CD4bs , of HIV gp120 (based on PDB 1G9N , YU2 strain). (b) NPC1bs , of EBOV-GP (based on PDB 5F1B , Zaire EBOV). Showing the accommodation of CD4-mimetic compound NBD-556 in the red dash circle. Hydrophobic surface in gray; CD4bs of HIV gp120 in magenta dash circle; NPC1bs of EBOV-GP in red dash circle.

Article Snippet: Human soluble CD4 (4D) protein (CD4-3167H) was also purchased from Creative Biomart Inc. CD4-Ig Recombinant protein was obtained from NIH HIV Reagent Program.

Techniques: Binding Assay

Journal: Translational Cancer Research

Article Title: Ovarian teratomas causing anti-N-methyl-D-aspartate receptor encephalitis: a case series from west China

doi: 10.21037/tcr-24-2126

Figure Lengend Snippet: Expression of CD4 and CD20 staining in different groups. (A) In the encephalitis group, CD20 positive lymphocytes infiltration into the squamous epithelium was apparent (the arrow points to the squamous epithelium). (B) In the encephalitis group, CD4 positive lymphocytes infiltration into the squamous epithelium was apparent (the arrow points to the squamous epithelium). (C) In control groups, the distribution of lymphocytes with CD4 positive was more dispersed (the arrow points to the squamous epithelium). (D) In control groups, the distribution of lymphocytes with CD20 positive was more dispersed (the arrow points to the squamous epithelium).

Article Snippet: The main antibodies (Abs) used were rabbit anti-human CD4 monoclonal antibody (dilution 1:100, Boster, China), rabbit anti-human CD20 polyclonal antibody (dilution 1:100, Boster, China), rabbit anti-human NMDAR2A antibody (dilution 1:100, Boster, China), rabbit anti-human NMDAR2B antibody (dilution 1:100, Tri-Eagle, China), rabbit anti-human NMDAR 1 antibody (dilution 1:100, Boster, China).

Techniques: Expressing, Staining, Control